Who are Entereg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Symproic, Movantik, Relistor, Revex, Narcan, LYBALVI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alvimopan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Entereg — Competitive Intelligence Brief

Entereg (ALVIMOPAN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid Antagonist. Area: Pain.

marketed Opioid Antagonist µ-opioid receptor Pain Small molecule Live · refreshed every 30 min

Target snapshot

Entereg (ALVIMOPAN) — Cubist Pharms. Alvimopan selectively antagonizes µ-opioid receptors in the gastrointestinal tract, improving motility without affecting central analgesia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Entereg TARGET	ALVIMOPAN	Cubist Pharms	marketed	Opioid Antagonist	µ-opioid receptor	2008-01-01
Symproic	NALDEMEDINE	Bdsi	marketed	Opioid Antagonist	Mu-type opioid receptor	2017-01-01
Movantik	NALOXEGOL	Averitas	marketed	Opioid Antagonist	Mu-type opioid receptor	2014-01-01
Relistor	METHYLNALTREXONE	Salix Pharms	marketed	Opioid Antagonist	Mu-type opioid receptor	2008-01-01
Revex	NALMEFENE	Hikma	marketed	Opioid Antagonist	Kappa-type opioid receptor	1995-01-01
Narcan	NALOXONE	Adapt	marketed	Opioid Antagonist	Mu-type opioid receptor	1971-01-01
LYBALVI	LYBALVI	Alkermes, Inc.	marketed	Atypical antipsychotic with opioid antagonist	D2 dopamine receptor, 5-HT7 serotonin receptor, mu-opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid Antagonist class)

Adapt · 1 drug in this class
Averitas · 1 drug in this class
Bdsi · 1 drug in this class
Cubist Pharms · 1 drug in this class
Hikma · 1 drug in this class
Salix Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Entereg — Competitive Intelligence Brief. https://druglandscape.com/ci/alvimopan. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab